Contraline Accelerates Growth with Expansion into New Laboratories and Addition of Key Team Members
Thursday, December 8th, 2016
CHARLOTTESVILLE, Virginia — Earlier this fall, Contraline moved its operations from the University of Virginia School of Medicine into its new headquarters in Charlottesville, called “ContraLab.” ContraLab is a 2200 sq. ft. office and laboratory space located at 1216 Harris Street. The laboratory space will be used primarily for research and product development including synthesizing and characterizing its vas-occlusive male contraceptive, Echo-V. Contraline will continue to maintain a close relationship with the University of Virginia, where small animal trials and clinical research are taking place. At a Grand Opening celebration later this month, Contraline will officially name the lab “The Herr Lab” after the company’s co-founder, Dr. John Herr, who passed away earlier this year.
Kevin Eisenfrats, Contraline’s co-founder and CEO, states, “Moving into our own headquarters signifies the next stage of opportunity and growth for Contraline. ContraLab provides the ability for us to add to our scientific team, build on our company culture, and focus on product development in an environment defined by our needs.”
In addition to the new space, Contraline has recently added key new members to the team. Joining Contraline as chief operating officer is Nikki Hastings. Dr. Hastings is an operations executive, engineer, and entrepreneur. Previously, Nikki served as vice president of operations at HemoShear Therapeutics where she was on the founding team developing the core technology. She is experienced in technology transfer and commercialization, organizational development and growth, laboratory build-out, development of internal processes and recruiting strategies. Nikki received her Ph.D. in biomedical engineering from the University of Virginia.
Joining the product development team is UVA Biomedical Engineering graduate, Eric Moran. Eric has experience performing basic science as well as clinical research at the University of Virginia. He is also an author on one patent. At Contraline, Eric will be designing and conducting experiments related to Echo-V and will be involved in manufacturing and intellectual property management.
In addition, Dr. Barry Hinton has joined the Contraline team as a principal investigator. Dr. Hinton is a professor in cell biology at the University of Virginia and a renowned expert in male reproductive biology. In 2016, Dr. Hinton was a recipient of the “Distinguished Andrologist Award,” the highest award given annually by the American Society of Andrology.
Eisenfrats concluded, “Given the incredibly motivated and interdisciplinary team, Contraline is well on its path to successfully commercializing the first long-lasting, reversible male contraceptive.”